Evaxion Reports Positive Data for CMV Vaccine Program

Evaxion Biotech ( (EVAX) ) has shared an announcement.

On November 20, 2025, Evaxion A/S announced positive data from its cytomegalovirus (CMV) vaccine program, EVX-V1. The program, which leverages Evaxion’s AI-Immunology™ platform, has identified novel antigens that significantly reduce viral infection in preclinical models. This advancement is crucial as no CMV vaccine has been approved despite decades of research, highlighting the importance of these findings. The company continues to optimize and investigate these AI-derived antigens while exploring strategic partnerships to advance the vaccine into clinical phases.

The most recent analyst rating on (EVAX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall score is driven by strong earnings call highlights, including strategic partnerships and promising clinical results. However, financial instability and valuation concerns weigh heavily, reflecting the company’s ongoing challenges in achieving profitability.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion A/S is a pioneering TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company utilizes its proprietary AI platform to create novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion is committed to transforming patient lives by providing innovative and targeted treatment options.

Average Trading Volume: 1,598,436

Technical Sentiment Signal: Sell

Current Market Cap: $30.82M

For a thorough assessment of EVAX stock, go to TipRanks’ Stock Analysis page.